Girentuximab

Drug Profile

Girentuximab

Alternative Names: cG250; Monoclonal antibody G250; Rencarex; WX-G250

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Centocor
  • Developer WILEX AG
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Renal cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Renal cancer

Most Recent Events

  • 25 Apr 2016 Girentuximab is available for licensing as of 25Apr 2016. http://www.wilex.com
  • 08 Nov 2013 Girentuximab is available for licensing as of 08 Nov 2013. http://www.wilex.de
  • 31 Oct 2013 Prometheus terminates its licence for girentuximab in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top